The US DoJ issues a letter for monoclonal antibody manufacturers to expand their production during the COVID-19 pandemic and allows exchange of information

Department Of Justice Issues Business Review Letter To Monoclonal Antibody Manufacturers To Expedite And Increase The Production Of Covid-19 Mab Treatments* The United States Department of Justice announced today that it will not challenge proposed efforts by Eli Lilly and Company, AbCellera Biologics, Amgen, AstraZeneca, Genentech, and GlaxoSmithKline (together, the Requesting

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Department of Justice Antitrust Division, The US DoJ issues a letter for monoclonal antibody manufacturers to expand their production during the COVID-19 pandemic and allows exchange of information, 23 July 2020, e-Competitions July 2020, Art. N° 95960

Visites 200

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues